ESC 2018 Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.
ESC 2018 The PURE cohort study and three other studies showed reduced risk of CV disease and mortality with higher healthy diet score in general populations worldwide.
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.
Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.
This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.
Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.
Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
ADA 2018 In the long-term Danish Steno 2 study, interventions targeting complications were found to improve disease-free-life length, and costs were not higher than with conventional treatment.
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.
Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.